Introduction
This paper reports a long-term open follow-up study of patients with various rheumatic disorders including osteoarthritis, rheumatoid disease, ankylosing spondylitis and prolapsed intervertebral disc (PIVD) ( Table 1 ) treated with fenclofenac. All patients commenced fenclofenac therapy as in-patients for four weeks and were monitored weekly during this period. They were assessed thereafter, on an out-patient basis, with clinical and laboratorymonitoring, at ten-weekly intervals. At each visit patients were assessed with regard to their disease stage, functional capacity and disease activity. The patient's self-assessment of pain and stiffness was recorded at each visit along with doctor's overall assessment of patient's status. The dose varied between 600 and 1200 mg per day, with the bulk of patients requiring 600-900 mg of fenclofenac daily (Table 3) . Laboratory monitoring included estimation of hemoglobin, white cell count, erythrocyte sedimentation rate, liver function tests, renal function tests and stool examination for occult blood. Renal function was assessed by means of the following tests: blood urea, serum creatinine, Fishberg test for renal concentrating ability, and urinalysis for glucose, cells, casts, protein, blood and -ulture. The study has been going on for about twelve months and is still continuing.
Results
As the bulk of patients were osteoarthritics, the main parameter measured was that of pain. This was recorded by means of a visual analogue scale (Berry & Huskisson 1972) for both overall and night pain, and both were shown to be significantly reduced (paired t test). The results for all patients are shown in Table 4 and those for osteoarthritic patients alone in Table 5 . Table 6 . This result might be expected from the small number of patients involved. The main purpose of this study, apart from the assessment of clinical efficacy, was to assess clinical tolerance and the effect of the drug on laboratory parameters. Nine patients had to be withdrawn from the trial because of side-effects (Table 7) . Two patients, both male, complained of dyspepsia. One male patient complained of diminished visual acuity after having been on fenclofenac for six months. He was seen by a consultant ophthalmologist whose opinion was that the patient's visual problem was related to a refractive error and the onset of presbyopia, and not related to fenclofenac therapy. One female patient complained of blurred vision which seemed to clear on cessation of fenclofenac. This patient, however, has a psychiatric history and had been on anti-depressants at the time. In addition, she 41 had been admitted with an overdose of Seconal in February 1977. Implication of fenclofenac with her visual problem, therefore, seemed doubtful. One male patient, who presented with Si root lesion due to PIVD, complained of loss of libido. There was no evidence of other sacral nerve roots being involved but in spite of reassurance the patient felt that he should discontinue fenclofenac. Two patients showed a tendency for the blood urea to rise. Both of these patients had a blood urea which was somewhat above normal limits when they started on fenclofenac but showed a drop in blood urea levels after cessation of fenclofenac (Table 8 ). Both patients were normotensive and liver function tests including SGOT, and gamma glutamic transferase, were normal throughout their study.
Two male patients were withdrawn, one complaining of dizziness and the other of a blotchy, itchy, facial eruption, urticarial in character. Four patients discontinued fenclofenac because of lack of response. Three female patients and one male patient were lost to the study because of change of address.
Of the remaining patients in the study, 8 complained of side-effects but these were apparently tolerable; the patients felt that the benefits from fenclofenac outweighed the side-effects (Table 9) .
Six of these patients, 5 male and one female, had gastrointestinal problems. One of the male patients presenting with osteoarthritis complained of acid regurgitation and diarrheea. However, he had this problem with other anti-inflammatory agents in the past. Barium meal and barium enema were both negative. One male patient complained of loose motions. Two patients, both male, complained of impairment of taste sensation but the cranial nerves were normal on examination. Both of these patients had osteoarthritis. This complaint, however, was not severe enough to discontinue fenclofenac. One male patient developed conjunctivitis for which he was seen by the ophthalmologist who prescribed a local ointment.
There was a complaint of leg cramps by one female osteoarthritic patient who showed evidence of peripheral vascular insufficiency and the condition seemed to settle down with a vasodilator in the form of Hexopal. It was interesting to note that of the 6 patients who complained of gastrointestinal side-effects, 4 were having other drugs in addition to fenclofenac.
Discussion
Surveying the results it would seem that fenclofenac is generally well tolerated and clinically beneficial in reducing pain and stiffness and improving mobility. Rheumatoid patients have shown evidence of reduced inflammation, diminished pain and stiffness and reduction in joint size. Of the patients complaining of dyspepsia while on fenclofenac, a number were on drugs other than fenclofenac at the same time and some of the patients had a previous history of dyspepsia with anti-inflammatory agents. The 2 patients showing a rise in blood urea already had marginally raised levels when they commenced fenclofenac therapy, but both of them did show a drop when fenclofenac was withdrawn. In none of the patients complaining of visual problems could these be ascribed to fenclofenac, nor could the complaints of loss of libido or leg cramps.
Conclusion
In conclusion it would seem that fenclofenac is a fairly well tolerated and reasonably efficient antirheumatic agent. 
